- Home
- DGAC vs BCYC Comparison
DGAC vs BCYC Comparison
Compare DGAC & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DGAC | BCYC |
|---|---|---|
| Founded | 2026 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.5M | 256.5M |
| IPO Year | 2026 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DGAC | BCYC |
|---|---|---|
| Price | $10.05 | $3.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $9.17 |
| AVG Volume (30 Days) | 54.7K | ★ 397.2K |
| Earning Date | N/A | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $3.33 |
| 52 Week High | $10.13 | $7.83 |
Technical Indicators
Market Signals| Indicator | DGAC | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 40.46 |
| Support Level | $9.98 | N/A |
| Resistance Level | $10.13 | $4.08 |
| Average True Range (ATR) | 0.02 | 0.21 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 42.86 | 13.71 |
Price Performance
Historical ComparisonAbout DGAC Disciplined Growth Acquisition Corporation
Disciplined Growth Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.